Sensorion achieves milestones in Phase II trial
French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
Entries by Thomas Gabrielczyk
Rentschler doubles cGMP capacity
In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
SciRhom GmbH closes €63m Series A financing
German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
Ligand Pharma to acquire Apeiron Biologics
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
EuroscreenFast and GW Vitek announce distribution partnership in Korea
Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.
EMA-Gate: PharmaMar wins suit against EMA
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.
Anacura aquires Ohmx.bio
Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
Ten drug recommendations by EMA
EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Nyxoah signs a €37.5m loan with the European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). The agreement is backed by the European Commission’s InvestEU program. Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S.